logo
  • About us
    • The Company in brief
    • Strategy
    • Market
    • Organisation
      • Management
      • Board of Directors
  • Our Drug Projects
    • Science
    • Pipeline
    • Our ongoing study
    • Disorders
      • Primary Biliary Cholangitis (PBC)
      • Hepatic Encephalopathy (HE)
      • Potential expansion
  • Our ongoing study
  • Investors
    • Financial Reports
    • Corporate Governance
    • General meetings
    • Calendar
    • Press Releases
  • Media
    • Press Releases
    • Presentations and posters
    • Subscribe
  • Contact

Presentations and posters

CEO Viktor Drvota presents at Redeye Theme Event Neurology 2025 – October 15

POSTER: CEO Viktor Drvota presents at Redeye Theme Event Neurology 2025 – October 15

EASL 2025: CGI-S Scale for PBC – Results of a focused training programme

EASL 2025: CGI-S Scale for PBC – Validation of a clinical trials outcome tool

  • Media
    • Press Releases
    • Presentations and posters
    • Subscribe

IR contact

Viktor Drvota
Viktor Drvota
CEO and Chairman of the Board
[email protected]

Press releases

  • May 13, 2026
    Umecrine Cognition will present patient survey data at EASL 2026 suggesting golexanolone addresses critical unmet need in PBC
    STOCKHOLM – May 13, 2026. Umecrine Cognition today announced new data from the UK-PBC national cohort, to be presented at the EASL Congress 2026 in...
  • April 30, 2026
    Notice to attend the Annual Shareholders’ Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)
    The shareholders in Umecrine Cognition AB, reg. no. 556698- 3655, are hereby given notice to attend the annual general shareholders’ meeting at...
  • November 19, 2025
    Umecrine Cognition publishes review highlighting the therapeutic potential of golexanolone in treating neuroinflammatory disorders
    STOCKHOLM – November 19, 2025. Umecrine Cognition today announced that a review article on golexanolone, a first-in-class drug candidate targeting...
See all press releases

CONTACT

Viktor Drvota
CEO and Chairman of the Board
Phone +46 8-524 860 70
[email protected]

All contacts

VISITING ADDRESS

Umecrine Cognition AB
Karolinska Institutet Science Park
Nanna Svartz väg 6A,
171 65 Solna
Sweden

COMPANY INFORMATION

Umecrine Cognition AB
Registered office in Solna
Reg no 556698-3655

  • Cookies
  • Privacy Policy